Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sangart has announced that an independent data safety monitoring board has recommended the continuation of both Phase III clinical trials of Sangart's lead blood substitute product, Hemospan, under current protocols.
Subscribe to our email newsletter
This recommendation is based on the data safety monitoring board’s (DSMB) review of the blinded data from the first two-thirds of the 830 patients to be enrolled in two ongoing Phase III pivotal studies in Europe.
Robert Winslow, chairman, president and CEO of Sangart, said: “We are pleased to have a second positive DSMB recommendation as we continue to advance these important Phase III studies.”